Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Dougados, S. Vam der Linden, M. Leirisalo-Repo, B. Huitfeldt, R. Juhlin, E. Veys, et al.
Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study.
Arthritis Rheum, 38 (1995), pp. 618-627
[2.]
H. Xu, J.K. Sethi, G.S. Hotamisligil.
Transmembrane tumor necrosis factor (TNF)-alpha inhibits adipocyte differentiation by selectively activating TNF receptor 1.
J Biol Chem, 274 (1999), pp. 26287-26295
[3.]
H.M. Van Dullemen, S.J. Van Deventer, D.W. Hommes, H.A. Bijl, J. Jansen, G.N. Tytgat, et al.
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).
Gastroenterology, 109 (1995), pp. 129-135
[4.]
D.M. Knight, H. Trinh, J. Le, S. Siegel, D. Shealy, M. McDonough, et al.
Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.
Mol Immunol, 30 (1993), pp. 1443-1453
[5.]
B.J. Scallon, M.A. Moore, H. Trinh, D.M. Knight, J. Ghrayeb.
Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions.
Cytokine, 7 (1995), pp. 251-259
[6.]
J.M. Van den Brande, H. Braat, G.R. Van den Brink, H.H. Versteeg, C.A. Bauer, I. Hoedemaeker, et al.
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
Gastroenterology, 124 (2003), pp. 1774-1785
[7.]
T. Ten Hove, C. Van Montfrans, M.P. Peppelenbosch, S.J. Van Deventer.
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.
Gut, 50 (2002), pp. 206-211
[8.]
W.J. Sandborn, S.B. Hanauer, S. Katz, M. Safdi, D.G. Wolf, R.D. Baerg, et al.
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
Gastroenterology, 121 (2001), pp. 1088-1094
[9.]
R. Maini, E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, et al.
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Lancet, 354 (1999), pp. 1932-1939
[10.]
S.R. Targan, S.B. Hanauer, S.J. Van Deventer, L. Mayer, D.H. Present, T. Braakman, et al.
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
N Engl J Med, 337 (1997), pp. 1029-1035
[11.]
J.D. Canete, S.E. Martínez, J. Farres, R. Sanmartí, M. Blay, A. Gómez, et al.
Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies.
Ann Rheum Dis, 59 (2000), pp. 263-268
[12.]
J. Gratacós, A. Collado, X. Filella, R. Sanmartí, J. Canete, J. Llena, et al.
Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity.
Br J Rheumatol, 33 (1994), pp. 927-931
[13.]
J. Braun, M. Bollow, L. Neure, E. Seipelt, F. Seyrekbasan, H. Herbst, et al.
Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis.
Arthritis Rheum, 38 (1995), pp. 499-505
[14.]
F. De Keyser, D. Elewaut, M. De Vos, K. De Vlam, C. Cuvelier, H. Mielants, et al.
Bowel inflammation and the spondyloarthropathies.
Rheum Dis Clin North Am, 24 (1998), pp. 785-813
[15.]
M. De Vos, H. Mielants, C. Cuvelier, A. Elewaut, E. Veys.
Long-term evolution of gut inflammation in patients with spondyloarthropathy.
Gastroenterology, 110 (1996), pp. 1696-1703
[16.]
P. Demetter, D. Baeten, F. De Keyser, M. De Vos, N. Van Damme, G. Verbruggen, et al.
Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex.
Ann Rheum Dis, 59 (2000), pp. 211-216
[17.]
F. Van den Bosch, E. Kruithof, D. Baeten, F. De Keyser, H. Mielants, E.M. Veys.
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.
Ann Rheum Dis, 59 (2000), pp. 428-433
[18.]
M. Stone, D. Salonen, M. Lax, U. Payne, V. Lapp, R. Inman.
Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis.
J Rheumatol, 28 (2001), pp. 1605-1614
[19.]
M. Breban, E. Vignon, P. Claudepierre, V. Devauchelle, D. Wendling, E. Lespessailles, et al.
Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study.
Rheumatology (Oxford), 41 (2002), pp. 1280-1285
[20.]
W.P. Maksymowych, G.S. Jhangri, R.G. Lambert, C. Mallon, H. Buenviaje, E. Pedrycz, et al.
Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.
J Rheumatol, 29 (2002), pp. 959-965
[21.]
J. Brandt, H. Haibel, J. Reddig, J. Sieper, J. Braun.
Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.
J Rheumatol, 29 (2002), pp. 118-122
[22.]
J. Brandt, H. Haibel, D. Cornely, W. Golder, J. González, J. Reddig, et al.
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
Arthritis Rheum, 43 (2000), pp. 1346-1352
[23.]
F. Van den Bosch, E. Kruithof, D. Baeten, A. Herssens, F. De Keyser, H. Mielants, et al.
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.
Arthritis Rheum, 46 (2002), pp. 755-765
[24.]
J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, W. Golder, et al.
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.
Lancet, 359 (2002), pp. 1187-1193
[25.]
J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, G. Burmester, et al.
Longterm efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
Arthritis Rheum, 48 (2003), pp. 2224-2233
[26.]
D. Van der Heijde, B. Dijkmans, P. Geusens, J. Sieper, K. DeWoody, P. Williamson, et al.
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
Arthritis Rheum, 52 (2005), pp. 582-591
[27.]
E. Cauza, M. Spak, K. Cauza, U. Hanusch-Enserer, A. Dunky, E. Wagner.
Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
Rheumatol Int, 22 (2002), pp. 227-232
[28.]
C. Antoni, C. Dechant, P.D. Hanns-Martin Lorenz, J. Wendler, A. Ogilvie, M. Lueftl, et al.
Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation.
Arthritis Rheum, 47 (2002), pp. 506-512
[29.]
C. Antoni, G.G. Krueger, K. De Vlam, C. Birbara, A. Beutler, C. Guzzo, et al.
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
Ann Rheum Dis, (2005),
[30.]
D. Baeten, E. Kruithof, F. Van den Bosch, N. Van den Bossche, A. Herssens, H. Mielants, et al.
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?.
Ann Rheum Dis, 62 (2003), pp. 829-834
[31.]
J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, W.D. Schwieterman, et al.
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
N Engl J Med, 345 (2001), pp. 1098-1104
[32.]
L. De Rycke, E. Kruithof, N. Van Damme, I.E. Hoffman, N. Van den Bossche, F. Van den Bosch, et al.
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
Arthritis Rheum, 48 (2003), pp. 1015-1023
[33.]
J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, G. Burmester, et al.
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.
Ann Rheum Dis, 64 (2005), pp. 229-234
[34.]
S. Generini, R. Giacomelli, R. Fedi, A. Fulminis, A. Pignone, G. Frieri, et al.
Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations.
Ann Rheum Dis, 63 (2004), pp. 1664-1669
Copyright © 2005. Elsevier España S.L. Barcelona
